|Articles|March 22, 2021
Nephron Pharmaceuticals Integrates STERIS VHP Biodecontamination System
Author(s)STERIS Life Sciences
This case study examines the benefits and challenges Nephron Pharmaceuticals Corporation faced integrating a STERIS VHP® Biodecontamination system into their high-volume compounding facility.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
3
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5